Best Supplier Of Maytansinol (7) CAS NO (57103-68-1) At Good Price

Maytansinol, with the Chemical Abstracts Service (CAS) number 57103-68-1, is a compound derived from maytansine, a natural product originally isolated from the East African shrub Maytenus serrata. Maytansinol possesses potent cytotoxic properties and is primarily investigated for its potential as an anticancer agent.

1. Origins and Natural Source Maytansinol is derived from maytansine, a cytotoxic ansamycin compound found in the bark and roots of the Maytenus serrata plant. Maytansine was first isolated in the 1970s and gained attention for its remarkable antitumor activity.

2. Chemical Structure Maytansinol belongs to the ansamycin class of compounds and is structurally related to the macrolide antibiotics. It consists of a complex polycyclic lactam ring system with an unsaturated side chain. The molecular formula of maytansinol is C31H46O10.

3. Mechanism of Action Maytansinol exerts its cytotoxic effects primarily by inhibiting microtubule assembly, leading to disruption of mitotic spindle formation and cell cycle arrest in the G2/M phase. This disruption ultimately induces apoptosis, or programmed cell death, in rapidly dividing cancer cells.

4. Anticancer Activity Maytansinol has shown promising anticancer activity in preclinical studies, particularly against various solid tumors, including breast cancer, lung cancer, and pancreatic cancer. Its potent cytotoxicity and mechanism of action make it an attractive candidate for cancer therapy.

5. Clinical Development Maytansinol has been investigated in early-phase clinical trials as a potential anticancer agent. However, its development has been hindered by challenges such as poor solubility, limited bioavailability, and systemic toxicity. Strategies to improve its pharmacokinetic profile and reduce off-target effects are being explored.

6. Drug Conjugates To overcome the limitations of maytansinol as a standalone therapeutic agent, researchers have developed antibody-drug conjugates (ADCs) incorporating maytansinol as the cytotoxic payload. These ADCs selectively deliver maytansinol to cancer cells, enhancing its therapeutic efficacy while minimizing systemic toxicity.

7. Future Directions Research into maytansinol and its derivatives continues to explore novel formulations, delivery strategies, and combination therapies to optimize its efficacy and safety as an anticancer agent. Advancements in drug delivery technologies and molecular targeting approaches hold promise for realizing the full therapeutic potential of maytansinol in cancer treatment.

8. Challenges and Considerations Challenges in the clinical development of maytansinol include the need for improved drug delivery systems to enhance tumor targeting, strategies to mitigate resistance mechanisms, and optimization of dosing regimens to balance efficacy and tolerability.

9. Potential Applications In addition to cancer therapy, maytansinol and its derivatives may have potential applications in other disease areas, including infectious diseases and neurodegenerative disorders. Further research is needed to explore these potential therapeutic avenues.

10. Conclusion Maytansinol holds promise as a potent anticancer agent with a unique mechanism of action. Despite challenges in its clinical development, ongoing research efforts continue to explore its therapeutic potential and pave the way for the development of next-generation cancer therapies.